Author: admin als-handoff

Nearly one in three adults who were still smoking or vaping after a prior ORCA trial had quit at the end of a year of cytisinicline treatment, with quit rates rising through the year. Among the participants new to cytisinicline (prior attempt on placebo), 39% had quit at the end of the year. Participants were…

Brings 15 years of pharma launch, health system, and direct-to-patient engagement experience as Achieve prepares for potential commercialization of cytisinicline. SEATTLE and VANCOUVER, British Columbia, October 7, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline…

SEATTLE and VANCOUVER, British Columbia, October 6, 2026 (GLOBENEWSWIRE) — Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that its board of directors approved stock option grants to purchase an aggregate…

Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisinicline. SEATTLE and VANCOUVER, British Columbia, October 1, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as…

SEATTLE and VANCOUVER, British Columbia, September 28, 2026 (GLOBE NEWSWIRE) – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and…